KSQ Therapeutics to present data at AACR 2022

By The Science Advisory Board staff writers

March 25, 2022 -- KSQ Therapeutics will give an oral presentation at the upcoming American Association for Cancer Research (AACR) 2022 annual meeting, held April 8-13.

The company will provide an overview of preclinical data on KSQ-4279, its USP1 inhibitor, as part of the ongoing phase I clinical trial of KSQ-4279 in advanced solid tumors.

USP1 was identified by KSQ's CRISPRomics platform as a novel synthetic lethal target in cancers with certain types of genomic instability, the company said.

The company's presentation will be on April 12 at 1:05-1:20 p.m. CT.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.